Trial Profile
A Phase II Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Monovalent and Multivalent RNA-based Vaccines in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2024
Price :
$35
*
At a glance
- Drugs Tozinameran (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors BioNTech
- 14 Nov 2023 Status changed from active, no longer recruiting to completed.
- 29 Jun 2023 Planned primary completion date changed from 1 Oct 2023 to 15 Aug 2023.
- 28 Mar 2023 Planned End Date changed from 1 Jan 2024 to 1 Oct 2023.